DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics announced that enrollment in its pivotal ReMEDy2 Phase 2/3 trial for DM199 has reached 75% of the 200-patient threshold required to trigger a pre-specified interim analysis. The independent Data Safety Monitoring Board (DSMB) will conduct this interim analysis to determine if a sample size re-estimation is recommended, with the final sample size expected to range between 300 and 728 patients.
Key figures
- Drug Name
- DM199 (rinvecalinase alfa)
- Phase Of Trial
- Phase 2/3
- Active sites
- 70
- Enrollment progress
- 75%
- Enrollment threshold
- 200
- Final sample size max
- 728
- Final sample size min
- 300
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.